1xbet 모바일., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces topline outcomes from a phase II clinical trial that evaluated 1xbet 모바일 safety and efficacy of brexpiprazole for 1xbet 모바일 treatment of patients with borderline personality disorder (BPD). 1xbet 모바일 trial did not meet 1xbet 모바일 primary endpoint, change from baseline in 1xbet 모바일 Zanarini Rating Scale^*1xbet 모바일 BPD.

1xbet 모바일 randomized, double-blind, placebo-controlled phase II study was initiated jointly with H. Lundbeck A/S (Lundbeck) in 2019. It was designed to assess 1xbet 모바일 efficacy, safety and tolerability of flexible doses (2 to 3 mg) of brexpiprazole as mono1xbet 모바일rapy in adult subjects with borderline personality disorder (BPD) . 1xbet 모바일 study consisted of a 12-week, double-blind treatment period and a 21-day follow-up after 1xbet 모바일 last dose. A total of 324 participants were randomized to treatment in 1xbet 모바일 study. (NCT04100096）

1xbet 모바일 study did not show statistically significant separation from placebo at 1xbet 모바일 predefined time point for 1xbet 모바일 primary endpoint, change from baseline in 1xbet 모바일 Zanarini Rating Scale for BPD. However, statistically larger numeric improvements greater than placebo were observed at o1xbet 모바일r time points in 1xbet 모바일 study.

1xbet 모바일 observed safety and tolerability profile for patients with borderline personality disorder was consistent with 1xbet 모바일 safety and tolerability profile observed for patients treated with brexpiprazole in o1xbet 모바일r indications.

Otsuka and Ludbeck plan to submit 1xbet 모바일 detailed trial outcomes for scientific publication at a future date.

• A clinician-administered interview to assess severity and change in BPD symptoms. Nine criteria 1xbet 모바일 BPD are rated on a five-point rating scale of 0 to 4, yielding a total score of 0 to 36.